We are advancing a growing pipeline of oncology therapies and diagnostics to enable a theranostic approach to cancer treatment, with the promise of allowing patients to live longer, healthier lives.

We have hundreds of compounds in our Intellectual Property Portfolio.

Currently RāC℞ has multiple opportunities in the pipeline

Ax-101

An immune system modulatory drug, the First-in-Human trial showed no adverse effects and efficacy in multiple cancers.

Glutamine transport (ASCT2) inhibitors

V-9302 proven in-vivo by RāC℞ and 3rd parties in multiple human cancers. Currently pursuing a group of improved validated hits as ASCT2 inhibitors – weakening cancer cells and strengthening the immune system.

Ax-101

An immune system modulatory drug, the First-in-Human trial showed no adverse effects and efficacy in multiple cancers.

Glutamine transport (ASCT2) inhibitors

V-9302 proven in-vivo by RāC℞ and 3rd parties in multiple human cancers. Currently pursuing a group of improved validated hits as ASCT2 inhibitors – weakening cancer cells and strengthening the immune system.